arrow
F

Federica Papaccio

and dentistry
H指数:26
被引数:2,919

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAP of molecular analyses in real-worlD oncology centers – MAPpaMoNDO: a study of the translational research Young GOIM group

现实世界肿瘤中心分子分析地图——MAPpaMoNDO:青年GOIM组转化研究的研究

2026-08-180
OA
RAS Inhibitors: Changing the Paradigm from the Undruggable

RAS抑制剂:改变不可成药靶点的范式

2026-07-280
OA
Synergistic effects of oncogene inhibition and pyruvate dehydrogenase kinase blockade in resistant NSCLC cells

癌基因抑制和丙酮酸脱氢酶激酶阻断在耐药NSCLC细胞中的协同效应

2025-08-080
OAAI
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer

DNA-PK 抑制可维持小细胞肺癌的先天抗肿瘤免疫反应。

2025-03-010
OAAI
Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids

通过整合组学和患者源性类器官解码结直肠癌中的染色体不稳定性见解

2025-02-280
OA
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer

将免疫检查点抑制剂与新型疗法相结合的景观: 对抗乳腺癌的秘密联盟

2024-11-010
OAAI
Mitochondrial transfer from Adipose stem cells to breast cancer cells drives multi-drug resistance
2024-06-149
OAAI
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer
2024-04-054
OAAI
Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction

用于药物敏感性预测的晚期结直肠癌患者衍生的类器官的蛋白质转录组学分析

2023-01-0629
OAAI
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
2021-09-0719
OAAI